Egetis Ends Takeover Talks To Focus On Emcitate

Filings For Rare Disease Drug Imminent

The Swedish firm has decided to pass on a bid from a proposed buyer which would have involved a healthy premium but “considerably undervalued” its long-term prospects.

Broken deal
• Source: Shutterstock

Egetis Therapeutics AB has been the subject of M&A speculation of late but suitors are going to need deep pockets if they want to get hold of the Swedish biotech, as one thwarted potential buyer has just found out.

Having revealed at the end of March that it was in discussions with various groups regarding a potential acquisition," Egetis has now announced that discussions, "which were triggered by an unsolicited approach by an external party," have been terminated

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business